SYDNEY and DUBLIN and JOHANNESBURG, Jan. 23, 2026 /PRNewswire/ -- Sigenergy, a global energy storage innovator, has been ranked the No. 1 energy storage brand in multiple international markets, including Australia, Ireland, and South Africa, according to the latest reports from SunWiz, an independent solar and energy consultancy.
Across these markets, SunWiz data confirms Sigenergy's market leadership in energy storage system market share by total installed capacity across the 0–1000 kWh range, reflecting broad installer adoption and strong customer preference. In Australia, Ireland, and South Africa, Sigenergy is the most widely selected energy storage brand among installers, reinforcing its position as a leading supplier in both mature and fast-growing energy markets.
In addition, Sigenergy has maintained its position as the No. 1 battery manufacturer in Australia by blended capacity[1] since March 2025. Based on SunWiz data, the company has held this top ranking for ten consecutive months, underscoring sustained market leadership rather than a short-term surge.
Sigenergy's strong regional performance reflects a consistent global growth trajectory. On a worldwide basis, Frost & Sullivan has ranked Sigenergy No. 1 in the stackable all-in-one Distributed Energy Storage System category. In 2024, Sigenergy shipped 475 MWh in this segment, capturing a 28.6 percent share of the global market.
Founded in 2022, Sigenergy has rapidly emerged as one of the fastest-growing companies in the global energy storage industry, driven by a focus on innovation, product reliability, and installer-centric design.
| [1] Blended capacity refers to the total energy capacity (in kilowatt-hours, kWh) of residential battery systems proposed, sold, and installed. |
[1] Blended capacity refers to the total energy capacity (in kilowatt-hours, kWh) of residential battery systems proposed, sold, and installed.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sigenergy Ranked No. 1 Energy Storage Brand Across Multiple Global Markets, According to SunWiz
TIANJIN, China, Jan. 26, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency's Master File acknowledgement letter, issued on January 9, 2026, incorporates the "Tasly 3P Characterization of MSCs Assay" (MF 32345) into its regulatory framework. This step provides long-sought guidance to ensure the consistent, safe, and effective clinical use of MSCs.
Historically misclassified as stem cells, MSCs have been associated with variable clinical outcomes due to a lack of specific quality benchmarks. The newly recognized " 3P " assay directly addresses this by evaluating three core attributes: Property (cell identity), Purity (freedom from contaminants), and Potency (functional activity). This focus ensures that therapeutic MSC products are accurately defined, devoid of heterogeneous cell populations, and biologically potent. The introduction of the Tasly 3P assay marks a pivotal shift toward normalized characterization of MSCs. It mitigates historical risks such as tumor formation and therapeutic inconsistency while empowering clinicians and patients to verify cell quality before treatment. As the first FDA-recognized protocol of its kind, it establishes a new benchmark for the field and accelerates the transition in regenerative medicine from a stem-cell-centric model to a stromal cell-focused paradigm.
By endorsing a standard that aligns with the modern scientific understanding—that MSCs primarily function via paracrine signaling, not differentiation—the FDA is closing a critical regulatory gap. This alignment with updated International Society for Cell & Gene Therapy guidelines is poised to streamline Investigational New Drug applications, enhance clinical trial reliability, and foster global harmonization in MSC product evaluation.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
